Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
1.670
-0.210 (-11.17%)
At close: Nov 3, 2025, 4:00 PM EST
1.720
+0.050 (2.99%)
After-hours: Nov 3, 2025, 4:40 PM EST
Ernexa Therapeutics Revenue
Ernexa Therapeutics had revenue of $488.00K in the twelve months ending June 30, 2025, up 201.23% year-over-year. In the year 2024, Ernexa Therapeutics had annual revenue of $582.00K with 755.88% growth.
Revenue (ttm)
$488.00K
Revenue Growth
+201.23%
P/S Ratio
11.19
Revenue / Employee
$81,333
Employees
6
Market Cap
13.19M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 582.00K | 514.00K | 755.88% |
| Dec 31, 2023 | 68.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
ERNA News
- 5 days ago - Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer - PRNewsWire
- 4 weeks ago - Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa - GlobeNewsWire
- 5 weeks ago - Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit - GlobeNewsWire
- 6 weeks ago - Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research - GlobeNewsWire
- 7 weeks ago - Ernexa Therapeutics Provides Update on Operational Excellence and Performance - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 4 months ago - Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development - GlobeNewsWire